Combining HIE, eRx database to EHRs improves med list accuracy

Combining the data of EHRs, a commercial medication database and a community health information exchange increased the accuracy of patients' medication lists, according to a study published in the American Journal of Managed Care.

Researchers analyzed EHR data for 858 patients who were admitted at two New York hospitals in the same healthcare system between September 2010 and April 2011. The patients were prescribed a total of 7,731 medications.

Physicians at the hospitals were able to access the EHRs, HIE and database. When researchers compared data from the three sources with medication lists that were compiled by patients and verified, they found that EHRs captured 80 percent of patients' medications accurately; the commercial medication database accurately captured 45 percent; and the HIE accurately captured 37 percent.

When all three data sources were combined, however, they captured 91 percent of patients' medication lists accurately.

The researchers attributed the combination of data sources on patient medication lists as helping providers "improve patient safety by improving patients' recall of their own medication history and allergy information, as well as by reducing medication discrepancies."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.